Women with early-stage breast cancer could benefit from taking an estrogen-suppressing drug for 10 years rather than the standard five, researchers reported here on Sunday, citing the results of a new study.
In the study, postmenopausal women who took a drug known as an aromatase inhibitor for an additional five years lowered the risk of their cancer returning or of a new case of cancer occurring in the other breast.
Read Full Article »
